Has Timothy Moore, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,111,326 in general payments to Timothy Moore, MD across 477 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Timothy Moore, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Timothy Moore, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Timothy Moore, MD

Medical Oncology · Columbus, OHNPI 1144278243

Payments from drug & device makers

$1,111,326in general payments, 2019–2025

Across 477 payments — averaging $2329.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$428K
Eli Lilly$168K
Seagen Inc.$166K
Genentech, Inc.$117K
Alkermes, Inc.$80K
Clovis Oncology, Inc.$73K
plus $79K from 47 others

$4,726in research payments, 2019–2025

Across 1 payment — averaging $4726.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$5K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	95	$428,409
Eli Lilly	13	$168,118
Seagen Inc.	118	$165,821
Genentech, Inc.	25	$117,065
Alkermes, Inc.	5	$79,720
Clovis Oncology, Inc.	15	$73,382
AstraZeneca	7	$32,437
Takeda Pharmaceuticals U.S.A., Inc.	19	$14,260
Pfizer	11	$8,311
Jazz Pharmaceuticals Inc.	1	$3,150
Rigel Pharmaceuticals, Inc.	9	$3,037
Beigene USA, Inc.	4	$2,767
Sanofi	6	$2,503
Karyopharm Therapeutics Inc.	5	$2,321
Gilead(2 entities)	7	$1,811
Epizyme, Inc.	1	$1,250
Daiichi Sankyo Inc.	3	$1,207
Caris MPI, Inc.	2	$1,044
Geron Corporation	1	$780
Pharmaand GmbH	1	$750
Eisai Inc.	22	$378
Athenex Pharmaceutical Division, LLC	2	$350
Fennec Pharmaceuticals, Inc.	1	$212
Novartis	10	$186
Adaptive Biotechnologies Corporation	2	$170
Bristol Myers Squibb	9	$170
E.r. Squibb & Sons, L.L.C.	8	$163
Regeneron Healthcare Solutions, Inc.	3	$160
AVEO Pharmaceuticals, Inc.	5	$138
Johnson & Johnson	6	$117
Taiho Oncology, Inc.	8	$114
AbbVie	4	$102
Ipsen Biopharmaceuticals, Inc	2	$97
EMD Serono, Inc.	7	$93
Coherus Oncology, Inc.	5	$83
Exelixis Inc.	3	$83
Amgen	5	$75
Agios Pharmaceuticals, Inc.	2	$64
Array Biopharma Inc	3	$60
Pharmacyclics LLC, An Abbvie Company	2	$44
AMAG Pharmaceuticals, Inc.	2	$39
CTI Biopharma Corp.	2	$38
GSK	2	$36
Acceleron Pharma, Inc.	2	$33
Iovance Biotherapeutics, Inc.	2	$31
Foundation Medicine, Inc.	2	$27
Dendreon Pharmaceuticals LLC	2	$25
Siemens Medical Solutions USA, Inc.	1	$24
Immunogen, Inc.	1	$15
Secura Bio, Inc.	1	$15
Lilly USA, LLC	1	$14
ADC Therapeutics America, Inc.	1	$13
Dova Pharmaceuticals	1	$13

How this compares

$1,111,326 in reported general payments places this provider in the 80th percentile of 157 medical oncology providers in Ohio.

See all medical oncology providers in Ohio →

Medicare billing

Part B allowed, 2024

$1,433,593

Medicare patients

428

Services billed

55,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Columbus

Kai HeColumbus$10.9M
Timothy BurnsColumbus$7.2M
Dwight OwenColumbus$6.8M
David CarboneColumbus$5.4M
Manisha ShahColumbus$4.3M
Gregory OttersonColumbus$4.1M
Marcelo BonomiColumbus$4M
Christian RolfoColumbus$3.8M
Wendy RathmellColumbus$2.8M
John HaysColumbus$2.6M

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →